首页 > 最新文献

Climacteric最新文献

英文 中文
Perimenopausal combined hormonal contraception: focus on sexual function. 围绝经期联合荷尔蒙避孕:关注性功能。
IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-01 Epub Date: 2024-11-13 DOI: 10.1080/13697137.2024.2423872
Tevfik Yoldemir

Age alone should not be an absolute contraindication for any contraceptive methods. However, medical eligibility criteria for combined hormonal contraception (CHC) use must be taken into consideration when choosing an appropriate contraceptive method. Women should be counseled on the benefits and risks of CHC while in their 40s. If there are no contraindications, women may use CHC for contraception up until the age of 50 years. Loss of libido is a common symptom during the late 40s. While women associate this with hormone levels, libido is multifactorial and is influenced by family and work stress, tiredness, self-image, medications and the physical changes in their partner. During this stage, women might experience urogenital issues such as vaginal dryness, dyspareunia and bladder problems, which can further affect the woman's sexual function. Before attributing the cause of sexual dysfunction to CHC use, a complete gynecologic examination and a full biopsychosocial assessment of the woman and her partner should be conducted to define other potential causes. When CHC-related female sexual dysfunction is suspected, using an oral CHC with a higher estrogen dose, a vaginal contraceptive ring or a transdermal contraceptive patch, or switching to a progesterone-only pill or non-hormonal method, might be suggested.

年龄本身不应成为任何避孕方法的绝对禁忌症。不过,在选择适当的避孕方法时,必须考虑到使用联合荷尔蒙避孕法(CHC)的医疗资格标准。应向 40 多岁的女性提供有关 CHC 好处和风险的咨询。如果没有禁忌症,妇女可以使用 CHC 避孕至 50 岁。性欲减退是 40 岁后期的常见症状。虽然女性会将其与荷尔蒙水平联系起来,但性欲是多因素的,会受到家庭和工作压力、疲劳、自我形象、药物和伴侣身体变化的影响。在这一阶段,女性可能会遇到阴道干涩、性交困难和膀胱问题等泌尿生殖系统问题,这些问题会进一步影响女性的性功能。在将性功能障碍的原因归结为使用 CHC 之前,应对女性及其伴侣进行全面的妇科检查和全面的生物-心理-社会评估,以确定其他可能的原因。当怀疑女性性功能障碍与 CHC 有关时,可建议使用雌激素剂量较高的口服 CHC、阴道避孕环或透皮避孕贴片,或改用纯黄体酮避孕药或非激素避孕法。
{"title":"Perimenopausal combined hormonal contraception: focus on sexual function.","authors":"Tevfik Yoldemir","doi":"10.1080/13697137.2024.2423872","DOIUrl":"10.1080/13697137.2024.2423872","url":null,"abstract":"<p><p>Age alone should not be an absolute contraindication for any contraceptive methods. However, medical eligibility criteria for combined hormonal contraception (CHC) use must be taken into consideration when choosing an appropriate contraceptive method. Women should be counseled on the benefits and risks of CHC while in their 40s. If there are no contraindications, women may use CHC for contraception up until the age of 50 years. Loss of libido is a common symptom during the late 40s. While women associate this with hormone levels, libido is multifactorial and is influenced by family and work stress, tiredness, self-image, medications and the physical changes in their partner. During this stage, women might experience urogenital issues such as vaginal dryness, dyspareunia and bladder problems, which can further affect the woman's sexual function. Before attributing the cause of sexual dysfunction to CHC use, a complete gynecologic examination and a full biopsychosocial assessment of the woman and her partner should be conducted to define other potential causes. When CHC-related female sexual dysfunction is suspected, using an oral CHC with a higher estrogen dose, a vaginal contraceptive ring or a transdermal contraceptive patch, or switching to a progesterone-only pill or non-hormonal method, might be suggested.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"15-20"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of sexual counseling based on the PLISSIT model on improving the sexual function of postmenopausal women: a randomized controlled trial. 基于 PLISSIT 模型的性咨询对改善绝经后妇女性功能的影响:随机对照试验。
IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-13 DOI: 10.1080/13697137.2024.2429426
Molouk Jaafarpour, Nasrin Rashan, Mona Bahmani, Ashraf Direkvand-Moghadam

Objective: Menopause can impact women's physical and mental well-being, including sexual function. The present study aims to evaluate the effect of sexual counseling based on the PLISSIT model on improving the sexual function of postmenopausal women.

Methods: The randomized trial focused on postmenopausal married women who did not have any pre-existing health conditions. The intervention group were provided with personalized sexual counseling grounded in the PLISSIT model, whereas the control group were given educational pamphlets. Participants filled out the Female Sexual Function Index (FSFI) questionnaire and were categorized into two groups through randomized blocking, utilizing blocks of four and six. The main outcome measure was the average sexual function score assessed at the start of the study, as well as at 4 and 8 weeks following the intervention.

Results: A total of 60 eligible participants were included in the study. The mean ± standard deviation participant age was 58.7 ± 3.5 years. At week 4 following the intervention, statistically significant differences were observed between the study groups in the mean scores of sexual desire (p = 0.023), arousal (p = 0.002), orgasm (p = 0.0001), lubrication (p = 0.001) and satisfaction (p = 0.004). At week 8 following the intervention, significant differences were noted in the mean scores for sexual arousal (p = 0.001), orgasm (p = 0.000), lubrication (p = 0.031) and satisfaction (p = 0.004) between the study groups.

Conclusion: The sexual counseling based on the PLISSIT model can significantly improve sexual function in postmenopausal women, making it a valuable intervention for healthcare providers to consider in their practice.

目的绝经会影响女性的身心健康,包括性功能。本研究旨在评估基于 PLISSIT 模式的性咨询对改善绝经后妇女性功能的效果:随机试验主要针对绝经后的已婚妇女,她们在绝经前没有任何健康问题。干预组获得了以 PLISSIT 模式为基础的个性化性咨询,而对照组则获得了教育小册子。受试者填写了女性性功能指数(FSFI)问卷,并通过随机分组的方式被分为两组,每组 4 人和 6 人。主要结果指标是研究开始时以及干预后 4 周和 8 周的平均性功能评分:共有 60 名符合条件的参与者参与了研究。参与者的平均年龄为(58.7±3.5)岁。在干预后第 4 周,研究组之间在性欲(p = 0.023)、性唤起(p = 0.002)、性高潮(p = 0.0001)、润滑(p = 0.001)和满意度(p = 0.004)的平均得分上存在显著差异。干预后第 8 周,研究组之间在性唤起(p = 0.001)、性高潮(p = 0.000)、润滑(p = 0.031)和满意度(p = 0.004)的平均得分上存在显著差异:结论:基于 PLISSIT 模型的性咨询可显著改善绝经后妇女的性功能,是医疗保健提供者在实践中可考虑的一种有价值的干预措施。
{"title":"The effect of sexual counseling based on the PLISSIT model on improving the sexual function of postmenopausal women: a randomized controlled trial.","authors":"Molouk Jaafarpour, Nasrin Rashan, Mona Bahmani, Ashraf Direkvand-Moghadam","doi":"10.1080/13697137.2024.2429426","DOIUrl":"10.1080/13697137.2024.2429426","url":null,"abstract":"<p><strong>Objective: </strong>Menopause can impact women's physical and mental well-being, including sexual function. The present study aims to evaluate the effect of sexual counseling based on the PLISSIT model on improving the sexual function of postmenopausal women.</p><p><strong>Methods: </strong>The randomized trial focused on postmenopausal married women who did not have any pre-existing health conditions. The intervention group were provided with personalized sexual counseling grounded in the PLISSIT model, whereas the control group were given educational pamphlets. Participants filled out the Female Sexual Function Index (FSFI) questionnaire and were categorized into two groups through randomized blocking, utilizing blocks of four and six. The main outcome measure was the average sexual function score assessed at the start of the study, as well as at 4 and 8 weeks following the intervention.</p><p><strong>Results: </strong>A total of 60 eligible participants were included in the study. The mean ± standard deviation participant age was 58.7 ± 3.5 years. At week 4 following the intervention, statistically significant differences were observed between the study groups in the mean scores of sexual desire (<i>p</i> = 0.023), arousal (<i>p</i> = 0.002), orgasm (<i>p</i> = 0.0001), lubrication (<i>p</i> = 0.001) and satisfaction (<i>p</i> = 0.004). At week 8 following the intervention, significant differences were noted in the mean scores for sexual arousal (<i>p</i> = 0.001), orgasm (<i>p</i> = 0.000), lubrication (<i>p</i> = 0.031) and satisfaction (<i>p</i> = 0.004) between the study groups.</p><p><strong>Conclusion: </strong>The sexual counseling based on the PLISSIT model can significantly improve sexual function in postmenopausal women, making it a valuable intervention for healthcare providers to consider in their practice.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"74-80"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding knowledge across medical specialties in menopause research and practice: why it is so important for women's health.
IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI: 10.1080/13697137.2024.2437292
Rossella E Nappi, Tim Hillard
{"title":"Expanding knowledge across medical specialties in menopause research and practice: why it is so important for women's health.","authors":"Rossella E Nappi, Tim Hillard","doi":"10.1080/13697137.2024.2437292","DOIUrl":"https://doi.org/10.1080/13697137.2024.2437292","url":null,"abstract":"","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":"28 1","pages":"1-3"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors influencing seogeulpeum among middle-aged Korean women. 影响韩国中年女性 Seogeulpeum 的因素。
IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-01 Epub Date: 2024-11-13 DOI: 10.1080/13697137.2024.2421793
Hyeja Gu, Eunyoung Hong

Objective: This study aimed to examine factors associated with seogeulpeum (a feeling of loneliness and solitude) - including aging anxiety, menopausal symptoms, social support and self-efficacy - in middle-aged women to provide fundamental data for future research endeavors.

Methods: One hundred and fifty-nine women aged 40-60 years were recruited from two cities in Gyeongnam Province and Busan City. Gu and Eun's Seogeulpeum Scale was employed to evaluate seogeulpeum, alongside questionnaires to assess menopause status and symptoms, self-efficacy, social support and aging anxiety. To determine factors influencing seogeulpeum, a multiple stepwise regression analysis was conducted.

Results: The average seogeulpeum score was 2.4 ± 0.44, indicating a moderate level of seogeulpeum experienced by the participants. Seogeulpeum was positively correlated with aging anxiety and menopausal symptoms, and negatively with self-efficacy and social support, among which aging anxiety most significantly influenced seogeulpeum. Aging anxiety, menopausal symptoms and social support combined accounted for 60.9% of the variation observed in seogeulpeum.

Conclusions: The findings indicate the importance of health interventions aimed at reducing aging anxiety and menopausal symptoms and enhancing social support for promoting well-being and facilitating a healthy menopausal transition among middle-aged women. Additionally, seogeulpeum can serve as a valuable process indicator during this stage of multiple transitions for women.

研究目的本研究旨在探讨与中年女性孤独感(seogeulpeum)相关的因素,包括衰老焦虑、更年期症状、社会支持和自我效能感,从而为今后的研究工作提供基础数据:从庆尚南道和釜山两个城市招募了 159 名 40-60 岁的女性。采用 Gu 和 Eun 的 Seogeulpeum 量表对 Seogeulpeum 进行评估,同时使用调查问卷评估更年期状况和症状、自我效能感、社会支持和衰老焦虑。为了确定影响 Seogeulpeum 的因素,研究人员进行了多元逐步回归分析:平均 Seogeulpeum 得分为 2.4 ± 0.44,表明参与者经历了中等程度的 Seogeulpeum。Seogeulpeum 与衰老焦虑和更年期症状呈正相关,与自我效能感和社会支持呈负相关,其中衰老焦虑对 Seogeulpeum 的影响最大。衰老焦虑、更年期症状和社会支持加在一起占观察到的Seogeulpeum变化的60.9%:研究结果表明,旨在减少老年焦虑和更年期症状以及加强社会支持的健康干预措施对于促进中年女性的幸福感和更年期健康过渡非常重要。此外,在更年期妇女的多重过渡阶段,海藻胶可以作为一个有价值的过程指标。
{"title":"Factors influencing <i>seogeulpeum</i> among middle-aged Korean women.","authors":"Hyeja Gu, Eunyoung Hong","doi":"10.1080/13697137.2024.2421793","DOIUrl":"10.1080/13697137.2024.2421793","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to examine factors associated with <i>seogeulpeum</i> (a feeling of loneliness and solitude) - including aging anxiety, menopausal symptoms, social support and self-efficacy - in middle-aged women to provide fundamental data for future research endeavors.</p><p><strong>Methods: </strong>One hundred and fifty-nine women aged 40-60 years were recruited from two cities in Gyeongnam Province and Busan City. Gu and Eun's <i>Seogeulpeum</i> Scale was employed to evaluate <i>seogeulpeum</i>, alongside questionnaires to assess menopause status and symptoms, self-efficacy, social support and aging anxiety. To determine factors influencing <i>seogeulpeum</i>, a multiple stepwise regression analysis was conducted.</p><p><strong>Results: </strong>The average <i>seogeulpeum</i> score was 2.4 ± 0.44, indicating a moderate level of <i>seogeulpeum</i> experienced by the participants. <i>Seogeulpeum</i> was positively correlated with aging anxiety and menopausal symptoms, and negatively with self-efficacy and social support, among which aging anxiety most significantly influenced <i>seogeulpeum</i>. Aging anxiety, menopausal symptoms and social support combined accounted for 60.9% of the variation observed in <i>seogeulpeum</i>.</p><p><strong>Conclusions: </strong>The findings indicate the importance of health interventions aimed at reducing aging anxiety and menopausal symptoms and enhancing social support for promoting well-being and facilitating a healthy menopausal transition among middle-aged women. Additionally, <i>seogeulpeum</i> can serve as a valuable process indicator during this stage of multiple transitions for women.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"40-50"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyaluronic acid and erbium laser for the treatment of genitourinary syndrome of menopause. 透明质酸和铒激光治疗更年期泌尿生殖系统综合征。
IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-01 Epub Date: 2024-11-04 DOI: 10.1080/13697137.2024.2418492
Tiziana Fidecicchi, Marco Gambacciani

Objective: This study aimed to evaluate the effect of the vaginal erbium laser (VEL) in association with vaginal hyaluronic acid (HA) in postmenopausal women suffering from genitourinary syndrome of menopause (GSM).

Methods: One hundred sexually active postmenopausal women were selected and divided into three groups using a block randomization method; 10 women declined to participate. The remaining women received three laser applications at 30-day intervals; 22 women dropped out for personal reasons or protocol violations. Group 1 (n = 25) received VEL treatment (XS Fotona Smooth®; Fotona, Slovenia) alone; Group 2 (n = 22) received daily vaginal HA tablets for 10 days after VEL treatment, followed by a twice a week administration during the follow-up period; and Group 3 (n = 21) received daily HA tablets for 10 days before the first VEL treatment and for 10 days after each laser application, followed by a twice a week administration for the follow-up period. Vaginal dryness and dyspareunia were assessed at the screening visit, before VEL treatment, after 1 and 3 months from the last laser treatment, using the visual analog scale. Data were analyzed using one-way analysis of variance and a linear mixed model for repeated measures. The post-hoc test for the interaction between time and treatment was performed using Bonferroni correction.

Results: A significant (p < 0.001) improvement in both vaginal dryness and superficial dyspareunia was evident, with greater (p < 0.001) improvement in Group 2 and Group 3.

Conclusions: The results suggest that vaginal HA administration can improve the VEL effects on GSM in postmenopausal women.

研究目的本研究旨在评估阴道铒激光(VEL)与阴道透明质酸(HA)联合治疗绝经后泌尿生殖系统综合征(GSM)妇女的效果:方法:选取 100 名性生活活跃的绝经后妇女,采用整群随机法将其分为三组,其中 10 名妇女拒绝参加。其余妇女每隔 30 天接受三次激光治疗;22 名妇女因个人原因或违反方案而退出。第一组(25 人)只接受 VEL 治疗(XS Fotona Smooth®;斯洛文尼亚,Fotona);第二组(22 人)在 VEL 治疗后的 10 天内每天服用阴道 HA 片剂,随后在随访期间每周服用两次;第三组(21 人)在第一次 VEL 治疗前的 10 天内和每次激光治疗后的 10 天内每天服用 HA 片剂,随后在随访期间每周服用两次。在筛查、VEL 治疗前、最后一次激光治疗后 1 个月和 3 个月,使用视觉模拟量表对阴道干涩和排便困难进行评估。数据采用单因子方差分析和线性混合模型进行重复测量分析。使用 Bonferroni 校正对时间与治疗之间的交互作用进行了事后检验:结果:结果显示,阴道注射 HA 的疗效显著:结果表明,在绝经后妇女中使用阴道 HA 可以改善 VEL 对 GSM 的影响。
{"title":"Hyaluronic acid and erbium laser for the treatment of genitourinary syndrome of menopause.","authors":"Tiziana Fidecicchi, Marco Gambacciani","doi":"10.1080/13697137.2024.2418492","DOIUrl":"10.1080/13697137.2024.2418492","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the effect of the vaginal erbium laser (VEL) in association with vaginal hyaluronic acid (HA) in postmenopausal women suffering from genitourinary syndrome of menopause (GSM).</p><p><strong>Methods: </strong>One hundred sexually active postmenopausal women were selected and divided into three groups using a block randomization method; 10 women declined to participate. The remaining women received three laser applications at 30-day intervals; 22 women dropped out for personal reasons or protocol violations. Group 1 (<i>n</i> = 25) received VEL treatment (XS Fotona Smooth<sup>®</sup>; Fotona, Slovenia) alone; Group 2 (<i>n</i> = 22) received daily vaginal HA tablets for 10 days after VEL treatment, followed by a twice a week administration during the follow-up period; and Group 3 (<i>n</i> = 21) received daily HA tablets for 10 days before the first VEL treatment and for 10 days after each laser application, followed by a twice a week administration for the follow-up period. Vaginal dryness and dyspareunia were assessed at the screening visit, before VEL treatment, after 1 and 3 months from the last laser treatment, using the visual analog scale. Data were analyzed using one-way analysis of variance and a linear mixed model for repeated measures. The post-hoc test for the interaction between time and treatment was performed using Bonferroni correction.</p><p><strong>Results: </strong>A significant (<i>p</i> < 0.001) improvement in both vaginal dryness and superficial dyspareunia was evident, with greater (<i>p</i> < 0.001) improvement in Group 2 and Group 3.</p><p><strong>Conclusions: </strong>The results suggest that vaginal HA administration can improve the VEL effects on GSM in postmenopausal women.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"87-92"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperandrogenism after menopause: diagnostic evaluation. 绝经后雄激素过多:诊断评估。
IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-01 Epub Date: 2024-11-14 DOI: 10.1080/13697137.2024.2423874
Carolina Fux-Otta, Diana Torre, Peter Chedraui, Belén Melgarejo, Noelia Ramos, Mariana Di Carlo, Mariana Benzi, Victoria Banús, María Eugenia Estario, Susana Leiderman, Romina Gecchelin, Inés Bartolacci, Milena Tarletta, Cintya Ziperovich, Silvina Di Lella, Candelaria Aramayo, Lucila Martín, Celina Pereyra, Constanza Real, Patricia Dogliani, Mónica Ñañez, Mónica López, Gabriel Iraci, Gladys Fernández

Excessive androgen levels in women after menopause often result from an imbalance in ovarian steroid secretion: a rapid decline in estrogen secretion associated with a slow decrease in androgen secretion, compounded by a physiological decrease in sex hormone-binding globulin. Hyperandrogenism is associated with a higher risk of cardiovascular events and gynecological neoplasms, also impacting the emotional well-being of affected women. Therefore, the aim of these guidelines is to guide the clinical physician in the appropriate clinical and biochemical evaluation of hyperandrogenism after menopause, thus optimizing therapeutic outcomes. The most frequent consultation in this stage of life is facial hirsutism associated with hair loss. If the onset of signs is abrupt, severe, associated with virilization and accompanied by serum testosterone levels in the male range, it is necessary to rule out a tumoral origin. A thorough medical history guides the diagnosis. Determination of total testosterone using reliable methods and imaging studies are valid tools to assist when doubts arise in the differential diagnosis.

绝经后妇女体内雄激素水平过高,通常是由于卵巢类固醇分泌失衡所致:雌激素分泌迅速减少,雄激素分泌缓慢减少,再加上性激素结合球蛋白的生理性减少。高雄激素与心血管事件和妇科肿瘤的高风险有关,同时也会影响受影响妇女的情绪。因此,本指南旨在指导临床医生对绝经后的高雄激素症进行适当的临床和生化评估,从而优化治疗效果。这一阶段最常见的症状是面部多毛并伴有脱发。如果症状出现突然、严重、伴有男性化,且血清睾酮水平在男性范围内,则有必要排除肿瘤的可能。详尽的病史可为诊断提供指导。当鉴别诊断出现疑问时,使用可靠的方法测定总睾酮和影像学检查是有效的辅助工具。
{"title":"Hyperandrogenism after menopause: diagnostic evaluation.","authors":"Carolina Fux-Otta, Diana Torre, Peter Chedraui, Belén Melgarejo, Noelia Ramos, Mariana Di Carlo, Mariana Benzi, Victoria Banús, María Eugenia Estario, Susana Leiderman, Romina Gecchelin, Inés Bartolacci, Milena Tarletta, Cintya Ziperovich, Silvina Di Lella, Candelaria Aramayo, Lucila Martín, Celina Pereyra, Constanza Real, Patricia Dogliani, Mónica Ñañez, Mónica López, Gabriel Iraci, Gladys Fernández","doi":"10.1080/13697137.2024.2423874","DOIUrl":"10.1080/13697137.2024.2423874","url":null,"abstract":"<p><p>Excessive androgen levels in women after menopause often result from an imbalance in ovarian steroid secretion: a rapid decline in estrogen secretion associated with a slow decrease in androgen secretion, compounded by a physiological decrease in sex hormone-binding globulin. Hyperandrogenism is associated with a higher risk of cardiovascular events and gynecological neoplasms, also impacting the emotional well-being of affected women. Therefore, the aim of these guidelines is to guide the clinical physician in the appropriate clinical and biochemical evaluation of hyperandrogenism after menopause, thus optimizing therapeutic outcomes. The most frequent consultation in this stage of life is facial hirsutism associated with hair loss. If the onset of signs is abrupt, severe, associated with virilization and accompanied by serum testosterone levels in the male range, it is necessary to rule out a tumoral origin. A thorough medical history guides the diagnosis. Determination of total testosterone using reliable methods and imaging studies are valid tools to assist when doubts arise in the differential diagnosis.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"61-68"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of a therapeutic lifestyle modification intervention on health-related quality of life and sexual functioning and cardiometabolic health in perimenopausal Chinese women: a randomized controlled trial. 治疗性生活方式改变干预对围绝经期中国妇女健康相关生活质量、性功能和心脏代谢健康的影响:一项随机对照试验
IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-13 DOI: 10.1080/13697137.2024.2435879
Yuru Wang, Xiaoling Miao, Pramon Viwattanakulvanid

Objective: This study aimed to evaluate the effects of a therapeutic lifestyle modification (TLM) intervention on health-related quality of life, sexual functioning and cardiometabolic health in perimenopausal Chinese women.

Method: The study was a randomized controlled trial (registration number: ChiCTR2300070648). Ninety-four perimenopausal women aged between 40 and 55 years were randomly assigned in a 1:1 ratio to receive the TLM intervention or usual care for 12 weeks. Menopause-specific Quality of Life (MENQOL), Female Sexual Function Index (FSFI), pelvic floor muscle strength (PFMS) and composite cardiometabolic indicators were evaluated at baseline and post intervention.

Results: After 12 weeks, linear mixed-effects models showed that the TLM intervention led to a statistically significant improvement in MENQOL (-0.60, 95% confidence interval [CI] - 0.80 to -0.41), FSFI (3.82, 95% CI 2.03 to 5.61), resting heart rate (-5.44, 95% CI -10.40 to -0.48), waist circumference(-3.14, 95% CI -4.15 to -2.13) and body fat percentage (-4.25, 95% CI -6.92 to -1.58) compared to the control group. There were also statistically significant differences between the intervention (TLM) group and the control group in the proportions of PFMS (p = 0.006).

Conclusion: The TLM intervention effectively improved menopause-specific quality of life in midlife women, supported by enhancements in female sexual functioning and cardiometabolic health status.

研究目的本研究旨在评估治疗性生活方式改变(TLM)干预对围绝经期中国女性健康相关生活质量、性功能和心脏代谢健康的影响:本研究为随机对照试验(注册号:ChiCTR2300070648)。94名年龄在40至55岁之间的围绝经期妇女按1:1的比例被随机分配到接受TLM干预或常规护理,为期12周。在基线和干预后对绝经期生活质量(MENQOL)、女性性功能指数(FSFI)、盆底肌力(PFMS)和综合心脏代谢指标进行评估:结果:12 周后,线性混合效应模型显示,TLM 干预对 MENQOL(-0.60,95% 置信区间 [CI] - 0.80 至 -0.41)、FSFI(3.82, 95% CI 2.03 to 5.61)、静息心率(-5.44, 95% CI -10.40 to -0.48)、腰围(-3.14, 95% CI -4.15 to -2.13)和体脂百分比(-4.25, 95% CI -6.92 to -1.58)与对照组相比均有统计学意义的改善。干预组(TLM)与对照组在 PFMS 的比例上也有显著的统计学差异(P = 0.006):TLM干预有效改善了中年女性更年期特有的生活质量,并提高了女性的性功能和心脏代谢健康状况。
{"title":"Effects of a therapeutic lifestyle modification intervention on health-related quality of life and sexual functioning and cardiometabolic health in perimenopausal Chinese women: a randomized controlled trial.","authors":"Yuru Wang, Xiaoling Miao, Pramon Viwattanakulvanid","doi":"10.1080/13697137.2024.2435879","DOIUrl":"10.1080/13697137.2024.2435879","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the effects of a therapeutic lifestyle modification (TLM) intervention on health-related quality of life, sexual functioning and cardiometabolic health in perimenopausal Chinese women.</p><p><strong>Method: </strong>The study was a randomized controlled trial (registration number: ChiCTR2300070648). Ninety-four perimenopausal women aged between 40 and 55 years were randomly assigned in a 1:1 ratio to receive the TLM intervention or usual care for 12 weeks. Menopause-specific Quality of Life (MENQOL), Female Sexual Function Index (FSFI), pelvic floor muscle strength (PFMS) and composite cardiometabolic indicators were evaluated at baseline and post intervention.</p><p><strong>Results: </strong>After 12 weeks, linear mixed-effects models showed that the TLM intervention led to a statistically significant improvement in MENQOL (-0.60, 95% confidence interval [CI] - 0.80 to -0.41), FSFI (3.82, 95% CI 2.03 to 5.61), resting heart rate (-5.44, 95% CI -10.40 to -0.48), waist circumference(-3.14, 95% CI -4.15 to -2.13) and body fat percentage (-4.25, 95% CI -6.92 to -1.58) compared to the control group. There were also statistically significant differences between the intervention (TLM) group and the control group in the proportions of PFMS (<i>p</i> = 0.006).</p><p><strong>Conclusion: </strong>The TLM intervention effectively improved menopause-specific quality of life in midlife women, supported by enhancements in female sexual functioning and cardiometabolic health status.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"28-39"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-dose and ultra-low-dose estradiol and dydrogesterone in postmenopause: an analysis by body mass index. 绝经后低剂量和超低剂量雌二醇和地屈孕酮:按体重指数分析。
IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-01 Epub Date: 2024-10-30 DOI: 10.1080/13697137.2024.2418497
Mulan Ren, Qi Yu, Marcelo Graziano Custodio, Tommaso Simoncini, Rossella E Nappi, Tetiana Tatarchuk, Elke Kahler, Tony Piha, John C Stevenson

Objective: Oral, low-dose and ultra-low-dose continuous combined 17β-estradiol (E) plus dydrogesterone (D) reduce vasomotor symptoms (VMS) in postmenopausal women.

Methods: Two phase 3, double-blind studies were included. In the European study, postmenopausal women were randomized 2:1:2 to receive E0.5 mg/D2.5 mg (ultra-low dose), E1 mg/D5 mg (low dose) or placebo for 13 weeks. In the Chinese study, women were randomized 1:1 to receive E0.5 mg/D2.5 mg or placebo for 12 weeks. Post-hoc endpoints assessed in body mass index (BMI) subgroups (<25 kg/m2; ≥25 kg/m2) included number of hot flushes and moderate-to-severe hot flushes per day, and the proportion of women with amenorrhea.

Results: A total of 640 women were included. At the end of treatment, the mean (95% confidence interval) numbers of daily hot flushes were significantly lower (p ≤ 0.05) for all treatment groups versus placebo, with E0.5 mg/D2.5 mg (BMI < 25 kg/m2: 2.5 [1.9, 3.1]; BMI ≥ 25 kg/m2: 3.2 [2.5, 3.8]) and E1 mg/D5 mg versus placebo (BMI < 25 kg/m2: 2.7 [1.2, 4.2]; BMI ≥ 25 kg/m2: 2.3 [1.1, 3.5]) than with placebo (BMI < 25 kg/m2: 4.4 [3.8, 50]; BMI ≥ 25 kg/m2: 4.2 [3.6, 4.9]). A similar pattern was seen for moderate-to-severe hot flushes. The amenorrhea rate was high (79-98%) across both studies and BMI subgroups.

Conclusion: Oral, ultra-low-dose continuous combined E0.5 mg/D2.5 mg and low-dose continuous combined E1 mg/D5 mg alleviated postmenopausal VMS compared with placebo, irrespective of BMI.

目的:口服、低剂量和超低剂量连续联合使用 17β-estradiol (E) 加地屈孕酮 (D) 可减轻绝经后妇女的血管运动症状 (VMS):方法:纳入了两项 3 期双盲研究。在欧洲的研究中,绝经后妇女按 2:1:2 的比例随机接受 E0.5 毫克/D2.5 毫克(超低剂量)、E1 毫克/D5 毫克(低剂量)或安慰剂,为期 13 周。在中国的研究中,妇女按 1:1 的比例随机接受 E0.5 毫克/D2.5 毫克或安慰剂,为期 12 周。在体重指数(BMI)亚组(2;≥25 kg/m2)中评估的事后终点包括每天潮热和中度至重度潮热的次数,以及闭经妇女的比例:结果:共纳入了 640 名妇女。治疗结束时,与安慰剂相比,所有治疗组每天潮热的平均次数(95% 置信区间)均显著降低(p ≤ 0.05),其中 E0.5 mg/D2.5 mg(BMI < 25 kg/m2:2.5 [1.9, 3.1];BMI ≥ 25 kg/m2:3.2 [2.5,3.8])和 E1 mg/D5 mg 与安慰剂(BMI < 25 kg/m2:2.7 [1.2,4.2];BMI ≥ 25 kg/m2:2.3 [1.1,3.5])相比(BMI < 25 kg/m2:4.4 [3.8,50];BMI ≥ 25 kg/m2:4.2 [3.6,4.9])。中度至重度潮热的情况也类似。两项研究和 BMI 亚组的闭经率都很高(79%-98%):结论:与安慰剂相比,口服超低剂量连续联合 E0.5 mg/D2.5 mg 和低剂量连续联合 E1 mg/D5 mg 可减轻绝经后 VMS,与 BMI 无关。
{"title":"Low-dose and ultra-low-dose estradiol and dydrogesterone in postmenopause: an analysis by body mass index.","authors":"Mulan Ren, Qi Yu, Marcelo Graziano Custodio, Tommaso Simoncini, Rossella E Nappi, Tetiana Tatarchuk, Elke Kahler, Tony Piha, John C Stevenson","doi":"10.1080/13697137.2024.2418497","DOIUrl":"10.1080/13697137.2024.2418497","url":null,"abstract":"<p><strong>Objective: </strong>Oral, low-dose and ultra-low-dose continuous combined 17β-estradiol (E) plus dydrogesterone (D) reduce vasomotor symptoms (VMS) in postmenopausal women.</p><p><strong>Methods: </strong>Two phase 3, double-blind studies were included. In the European study, postmenopausal women were randomized 2:1:2 to receive E0.5 mg/D2.5 mg (ultra-low dose), E1 mg/D5 mg (low dose) or placebo for 13 weeks. In the Chinese study, women were randomized 1:1 to receive E0.5 mg/D2.5 mg or placebo for 12 weeks. Post-hoc endpoints assessed in body mass index (BMI) subgroups (<25 kg/m<sup>2</sup>; ≥25 kg/m<sup>2</sup>) included number of hot flushes and moderate-to-severe hot flushes per day, and the proportion of women with amenorrhea.</p><p><strong>Results: </strong>A total of 640 women were included. At the end of treatment, the mean (95% confidence interval) numbers of daily hot flushes were significantly lower (<i>p</i> ≤ 0.05) for all treatment groups versus placebo, with E0.5 mg/D2.5 mg (BMI < 25 kg/m<sup>2</sup>: 2.5 [1.9, 3.1]; BMI ≥ 25 kg/m<sup>2</sup>: 3.2 [2.5, 3.8]) and E1 mg/D5 mg versus placebo (BMI < 25 kg/m<sup>2</sup>: 2.7 [1.2, 4.2]; BMI ≥ 25 kg/m<sup>2</sup>: 2.3 [1.1, 3.5]) than with placebo (BMI < 25 kg/m<sup>2</sup>: 4.4 [3.8, 50]; BMI ≥ 25 kg/m<sup>2</sup>: 4.2 [3.6, 4.9]). A similar pattern was seen for moderate-to-severe hot flushes. The amenorrhea rate was high (79-98%) across both studies and BMI subgroups.</p><p><strong>Conclusion: </strong>Oral, ultra-low-dose continuous combined E0.5 mg/D2.5 mg and low-dose continuous combined E1 mg/D5 mg alleviated postmenopausal VMS compared with placebo, irrespective of BMI.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"21-27"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion. 乳腺癌和妇科癌症术后的全身激素治疗:意大利专家组的共识意见。
IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-01 Epub Date: 2024-11-06 DOI: 10.1080/13697137.2024.2418503
Angelo Cagnacci, Paola Villa, Giuseppina Paola Grassi, Nicoletta Biglia, Marco Gambacciani, Costantino Di Carlo, Francesca Nocera, Salvatore Caruso, Angelamaria Becorpi, Stefano Lello, Anna Maria Paoletti

The specific Italian Group of Study of the Menopause formulated a consensus opinion on the use of estrogen therapy (ET) or combined estro-progestin hormone therapy (HT) after breast and gynecological cancers. This consensus is based on the risk of recurrence of the specific cancer during ET/HT, the presence of steroid receptors in cancer cells, the use of adjuvant hormone therapies and data on the use of ET/HT after cancer. The following positions were reached. ET/HT can be used after vulvar cancers and melanoma, but with great caution after the rare adenocarcinomas. ET/HT can be used after cervical cancer, but ET should be used with caution after adenocarcinomas. ET/HT can be used after International Federation of Obstetrics and Gynecology (FIGO) stage I-II estrogen-dependent endometrial cancers, except in Black women, and can probably be used after estrogen-independent endometrial cancers. ET/HT cannot be administered or should be used with great caution after most uterine sarcomas. ET/HT can probably be used after ovarian neoplasms except for granulosa cell tumors, and with great caution after low-grade serous ovarian carcinoma and serous borderline ovarian tumors. ET/HT can be used with great caution in women after estrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer and is probably allowed after ER/PR-negative breast cancer.

意大利更年期研究小组就乳腺癌和妇科癌症术后使用雌激素疗法(ET)或雌孕激素联合疗法(HT)达成了共识。该共识基于 ET/HT 期间特定癌症的复发风险、癌细胞中类固醇受体的存在、辅助激素疗法的使用以及癌症后使用 ET/HT 的数据。会议达成了以下共识。外阴癌和黑色素瘤术后可以使用 ET/HT,但对于罕见的腺癌则要非常谨慎。宫颈癌术后可使用 ET/HT,但腺癌术后应慎用 ET。国际妇产科联盟(FIGO)Ⅰ-Ⅱ期雌激素依赖型子宫内膜癌(黑人妇女除外)可以使用 ET/HT,雌激素不依赖型子宫内膜癌可能也可以使用 ET/HT。大多数子宫肉瘤不能使用或应慎用 ET/HT。卵巢肿瘤(颗粒细胞瘤除外)可能可以使用 ET/HT,但低级别浆液性卵巢癌和浆液性边缘卵巢肿瘤则应慎用。雌激素受体(ER)/孕激素受体(PR)阳性乳腺癌患者可慎用 ET/HT,ER/PR 阴性乳腺癌患者可能可以使用 ET/HT。
{"title":"Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion.","authors":"Angelo Cagnacci, Paola Villa, Giuseppina Paola Grassi, Nicoletta Biglia, Marco Gambacciani, Costantino Di Carlo, Francesca Nocera, Salvatore Caruso, Angelamaria Becorpi, Stefano Lello, Anna Maria Paoletti","doi":"10.1080/13697137.2024.2418503","DOIUrl":"10.1080/13697137.2024.2418503","url":null,"abstract":"<p><p>The specific Italian Group of Study of the Menopause formulated a consensus opinion on the use of estrogen therapy (ET) or combined estro-progestin hormone therapy (HT) after breast and gynecological cancers. This consensus is based on the risk of recurrence of the specific cancer during ET/HT, the presence of steroid receptors in cancer cells, the use of adjuvant hormone therapies and data on the use of ET/HT after cancer. The following positions were reached. ET/HT can be used after vulvar cancers and melanoma, but with great caution after the rare adenocarcinomas. ET/HT can be used after cervical cancer, but ET should be used with caution after adenocarcinomas. ET/HT can be used after International Federation of Obstetrics and Gynecology (FIGO) stage I-II estrogen-dependent endometrial cancers, except in Black women, and can probably be used after estrogen-independent endometrial cancers. ET/HT cannot be administered or should be used with great caution after most uterine sarcomas. ET/HT can probably be used after ovarian neoplasms except for granulosa cell tumors, and with great caution after low-grade serous ovarian carcinoma and serous borderline ovarian tumors. ET/HT can be used with great caution in women after estrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer and is probably allowed after ER/PR-negative breast cancer.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"4-14"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the triglyceride-glucose index in postmenopausal osteoporosis. 绝经后骨质疏松症患者甘油三酯-葡萄糖指数的研究。
IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-05 DOI: 10.1080/13697137.2024.2429430
Busra Korpe, Caner Kose, Sumeyye Mermi, Samet Kutluay Ergorun, Huseyin Levent Keskin

Objective: This retrospective study aims to assess the association of the triglyceride-glucose index (TyG index) with postmenopausal osteoporosis and investigate longitudinal changes in TyG index levels in relation to osteoporosis risk.

Methods: Out of 704 women, after excluding those with osteopenia, a total of 517 patients who met the inclusion criteria were included. Participants were categorized based on T-scores derived from lumbar spine dual-energy X-ray absorptiometry scans. Demographic data, biochemical parameters and TyG index levels were analyzed. Logistic regression, correlation analysis and receiver operating characteristic (ROC) curve analysis were employed for statistical evaluation.

Results: The osteoporosis group (n = 254) exhibited significantly higher TyG index and triglyceride levels compared to controls (n = 263). Longitudinal analysis revealed significant increases in TyG index levels among women developing osteoporosis over time. ROC analysis demonstrated the TyG index's accuracy for osteoporosis (first TyG area under the curve [AUC]: 0.767, second TyG AUC: 0.818, p < 0.001). Regression analyses identified the TyG index as a significant factor associated with osteoporosis (odds ratio: 39.468, 95% confidence interval: 12.884-120.903, p < 0.001).

Conclusions: The TyG index emerges as a valuable indicator for postmenopausal osteoporosis. These results emphasize the need for integrating metabolic health indicators into osteoporosis management strategies, warranting further research into targeted interventions.

目的:本回顾性研究旨在评估甘油三酯-葡萄糖指数(TyG指数)与绝经后骨质疏松症的关系,并探讨TyG指数水平的纵向变化与骨质疏松症风险的关系。方法:704名女性中,剔除骨质减少者后,共纳入517例符合纳入标准的患者。根据腰椎双能x线吸收仪扫描得出的t评分对参与者进行分类。统计学资料、生化指标及TyG指数水平分析。采用Logistic回归、相关分析和受试者工作特征(ROC)曲线分析进行统计评价。结果:骨质疏松组(n = 254)的TyG指数和甘油三酯水平明显高于对照组(n = 263)。纵向分析显示,随着时间的推移,患骨质疏松症的女性TyG指数水平显著增加。ROC分析显示TyG指数对骨质疏松症的准确性(第一次TyG曲线下面积[AUC]: 0.767,第二次TyG曲线下面积:0.818,p p)。结论:TyG指数是绝经后骨质疏松症的一个有价值的指标。这些结果强调了将代谢健康指标纳入骨质疏松症管理策略的必要性,值得进一步研究有针对性的干预措施。
{"title":"Investigating the triglyceride-glucose index in postmenopausal osteoporosis.","authors":"Busra Korpe, Caner Kose, Sumeyye Mermi, Samet Kutluay Ergorun, Huseyin Levent Keskin","doi":"10.1080/13697137.2024.2429430","DOIUrl":"10.1080/13697137.2024.2429430","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective study aims to assess the association of the triglyceride-glucose index (TyG index) with postmenopausal osteoporosis and investigate longitudinal changes in TyG index levels in relation to osteoporosis risk.</p><p><strong>Methods: </strong>Out of 704 women, after excluding those with osteopenia, a total of 517 patients who met the inclusion criteria were included. Participants were categorized based on <i>T</i>-scores derived from lumbar spine dual-energy X-ray absorptiometry scans. Demographic data, biochemical parameters and TyG index levels were analyzed. Logistic regression, correlation analysis and receiver operating characteristic (ROC) curve analysis were employed for statistical evaluation.</p><p><strong>Results: </strong>The osteoporosis group (<i>n</i> = 254) exhibited significantly higher TyG index and triglyceride levels compared to controls (<i>n</i> = 263). Longitudinal analysis revealed significant increases in TyG index levels among women developing osteoporosis over time. ROC analysis demonstrated the TyG index's accuracy for osteoporosis (first TyG area under the curve [AUC]: 0.767, second TyG AUC: 0.818, <i>p</i> < 0.001). Regression analyses identified the TyG index as a significant factor associated with osteoporosis (odds ratio: 39.468, 95% confidence interval: 12.884-120.903, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>The TyG index emerges as a valuable indicator for postmenopausal osteoporosis. These results emphasize the need for integrating metabolic health indicators into osteoporosis management strategies, warranting further research into targeted interventions.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"81-86"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Climacteric
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1